miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Zheng L, Meng X, Li X, Zhang Y, Li C, Xiang C, Xing Y, Xia Y, Xi T.
Zheng L, et al. Among authors: li c, li x.
FASEB J. 2018 Feb;32(2):588-600. doi: 10.1096/fj.201700461RR. Epub 2018 Jan 4.
FASEB J. 2018.
PMID: 28939591
These results suggest that miR-125a-3p can function as a novel tumor suppressor in ER(+) breast cancer by targeting CDK3, which may be a potential therapeutic approach for TamR breast cancer therapy.-Zheng, L., Meng, X., Li, X., Zhang, Y., Li, C., Xian …
These results suggest that miR-125a-3p can function as a novel tumor suppressor in ER(+) breast cancer by targeting CDK3, which may be a pot …